<DOC>
	<DOC>NCT01270490</DOC>
	<brief_summary>The purpose of this study is to assess the feasibility and preliminary efficacy of interferon-gamma in combination with anidulafungin for the treatment of candidemia</brief_summary>
	<brief_title>Efficacy of Interferon-gamma in Combination With Anidulafungin for the Treatment of Candidemia</brief_title>
	<detailed_description />
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<criteria>Males or nonpregnant females (who must agree to use barrier methods of contraception during the study therapy period, women of childbearing age must have a negative urine pregnancy or serum test at baseline). Subjects who are 18 years of age or older Subjects with at least one positive blood culture isolation of Candida species from a specimen drawn within 96 hours prior to study entry. Subjects who have clinical evidence of infection AT SOME TIME WITHIN 96 HOURS PRIOR TO ENROLLMENT, including AT LEAST ONE of the following: Temperature &gt;37.8 ˚C on 2 occasions at least 4 hours apart or one measurement &gt; 38.2 ˚C Systolic blood pressure &lt;90 or a &gt;30 mmHg decrease in systolic BP from the subject's normal baseline. Signs of inflammation (swelling, heat, erythema, purulent drainage) from a site infected with Candida (eg, joint, skin, eye, bone, esophagus) Radiologic findings of invasive candidiasis Subject or their legal representative must sign a written informed consent form. Subjects with a history of allergy or intolerance to echinocandins or IFNgamma Subjects with a history of documented epileptic seizures Subjects with severe renal impairment (creatinine clearance less than 30/mL/min) Subjects with severe liver failure (impaired synthesis of proteins such as coagulation factors manifested by increased prothrombin time) Subjects with an absolute neutrophil count of less than 500/mm3 at study entry Women who are pregnant or lactating Subjects who are unlikely to survive more than 24 hours Subjects who have failed previous systemic antifungal therapy for the Candida spp. infection which is being studied. Subjects who have received more than 48 hours of systemic antifungal therapy for the current episode, within 96 hours prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>candidemia</keyword>
	<keyword>candida sepsis</keyword>
	<keyword>invasive fungal disease</keyword>
</DOC>